Findings present participants experiences and perceptions of facilitators and barriers to iOAT within a structural vulnerability context. The demographic characteristics of patients who participated in baseline and follow up interviews are presented in Table 2. Through iOAT, patients were able to receive other medications in addition to their HDM or DAM, such as anti-depressants, antiretroviral, and direct-acting antiviral medications.